

1 **Genome-wide fine-mapping improves identification of causal variants**

2

3 Yang Wu<sup>1,2,\*</sup>, Zhili Zheng<sup>2,3,4</sup>, Loic Thibaut<sup>2</sup>, Michael E. Goddard<sup>5,6</sup>, Naomi R. Wray<sup>2,7</sup>, Peter M.  
4 Visscher<sup>2,8</sup>, Jian Zeng<sup>2,\*</sup>

5

6 <sup>1</sup> Institute of Rare Diseases, West China Hospital of Sichuan University, Chengdu, China

7 <sup>2</sup> Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland,  
8 Australia

9 <sup>3</sup> Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge,  
10 Massachusetts, USA

11 <sup>4</sup> Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge,  
12 Massachusetts, USA

13 <sup>5</sup> Faculty of Veterinary and Agricultural Science, University of Melbourne, Parkville, Victoria,  
14 Australia

15 <sup>6</sup> Biosciences Research Division, Department of Economic Development, Jobs, Transport and  
16 Resources, Bundoora, Victoria, Australia

17 <sup>7</sup> Department of Psychiatry, University of Oxford, Oxford, UK

18 <sup>8</sup> Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department  
19 of Population Health, University of Oxford, Oxford, UK

20

21 \* Correspondence: Yang Wu ([yang.wu@wchscu.edu.cn](mailto:yang.wu@wchscu.edu.cn)), Jian Zeng ([j.zeng@uq.edu.au](mailto:j.zeng@uq.edu.au))

22 **Abstract**

23 Fine-mapping refines genotype-phenotype association signals to identify causal variants  
24 underlying complex traits. However, current methods typically focus on individual genomic  
25 segments without considering the global genetic architecture. Here, we demonstrate the  
26 advantages of performing genome-wide fine-mapping (GWFM) and develop methods to facilitate  
27 GWFM. In simulations and real data analyses, GWFM outperforms current methods in error  
28 control, mapping power and precision, replication rate, and trans-ancestry phenotype prediction.  
29 For 48 well-powered traits in the UK Biobank, we identify causal variants that collectively explain  
30 17% of the SNP-based heritability, and predict that fine-mapping 50% of that would require 2  
31 million samples on average. We pinpoint a known causal variant, as proof-of-principle, at FTO for  
32 body mass index, unveil a hidden secondary variant with evolutionary conservation, and identify  
33 new missense causal variants for schizophrenia and Crohn's disease. Overall, we analyse 599  
34 complex traits with 13 million SNPs, highlighting the efficacy of GWFM with functional  
35 annotations.

## 36 **Introduction**

37 Genome-wide association studies (GWAS) have successfully identified numerous genetic variants  
38 associated with complex traits<sup>1-3</sup>. However, the underlying causal variants for these traits are  
39 largely unknown. In a standard GWAS, the trait-variant associations are tested one at a time,  
40 leading to the discovery of clusters of mutually correlated marginal-association signals due to  
41 linkage disequilibrium (LD) between SNPs<sup>4</sup>. While post-GWAS methods such as LD clumping<sup>5</sup> or  
42 COJO<sup>6</sup> are used to identify independently significant association signals, SNPs prioritised by these  
43 methods are not necessarily the causal variants<sup>7,8</sup>.

44

45 Statistical fine-mapping, often employing a Bayesian mixture model (BMM), offers a direct  
46 approach to narrow down the likely causal variants<sup>9</sup>. In contrast to GWAS, which test marginal  
47 effects, fine-mapping aims to detect joint-association signals for causal inference, where the  
48 strength of joint association is assessed using the posterior inclusion probability (PIP). PIP is the  
49 probability of a SNP being included with a nonzero effect in the model, which, in theory, controls  
50 false discovery rate (FDR)<sup>10</sup>. Due to the computational burden and complexity of test hypotheses,  
51 current fine-mapping methods focus on genome-wide significant loci only or consider one  
52 genomic region at a time (e.g., a LD block), in isolation from the rest of the genome<sup>11-14</sup>. Methods  
53 differ mainly in the algorithm used to derive PIP. For example, FINEMAP<sup>12</sup> utilizes a shotgun  
54 stochastic search algorithm to explore possible causal configurations, and computes the PIP by  
55 averaging over those with non-negligible probabilities. SuSiE<sup>11</sup> and SuSiE-RSS<sup>14</sup> assume a sparse  
56 effect model and employ an iterative Bayesian stepwise selection approach to estimate the overall  
57 effect of each SNP by summing up multiple single-effect vectors. SuSiE-Inf<sup>13</sup> and FINEMAP-Inf<sup>13</sup>  
58 further extend the two models to include an infinitesimal component for improved modelling of  
59 polygenic architecture within a locus.

60

61 Despite being widely used, region-specific analysis has limitations. First, the prior specification  
62 of genetic architecture is crucial, but is often conservatively predetermined in these analysis<sup>11,12,15</sup>  
63 (e.g., prior probability of association set to one over the number of SNPs in the region), which can  
64 result in reduced power. Second, fine-mapping can benefit from incorporating functional genomic  
65 annotations<sup>16-18</sup>, but region-specific methods require step-wise procedures so that GWAS data  
66 and functional annotations are not modelled jointly<sup>19</sup>. Third, none of the current methods  
67 estimates the power of identifying the causal variants for a trait, which is critical to inform the

68 experimental design of a prospective study (such a power analysis is available in GWAS<sup>20</sup> but not  
69 in fine-mapping).

70

71 These limitations of current fine-mapping methods can be addressed through conducting a fine-  
72 mapping analysis using a genome-wide Bayesian mixture model (GBMM). GBMMs, which have  
73 been widely used for predicting breeding values in agricultural species<sup>21-23</sup> and complex trait  
74 phenotypes in humans<sup>24-27</sup>, have recently emerged as a method of GWFM<sup>28,29</sup>. Compared to  
75 conventional GWAS and region-specific fine-mapping approaches, GBMMs consider genome-  
76 wide SNPs simultaneously, which are all utilised to estimate the genetic architecture and  
77 functional prior<sup>27,28</sup>. For example, SNPs with the same class of functional annotation are present  
78 across the genome. By considering all SNPs jointly, the importance of a functional annotation in a  
79 local genomic region can be prioritised based on the evidence for association as a class across the  
80 genome. In GBMMs, Markov chain Monte Carlo (MCMC) sampling is often used for posterior  
81 inference, which is asymptotically exact and superior to the variational inference regarding  
82 accuracy<sup>30</sup>, but computationally challenging when analysing high-density SNPs. Fortunately,  
83 recent advances in methodology, such as SBayesRC<sup>27</sup>, have allowed fitting all common SNPs  
84 efficiently in a MCMC-based GBMM. Moreover, GBMMs estimate the polygenicity and variant  
85 effect size distribution<sup>22,24,26,27,31,32</sup>, providing an opportunity to predict the power of prospective  
86 studies with larger sample sizes. However, relevant theory and methods have not yet been  
87 developed.

88

89 In this study, we comprehensively assess the performance of GWFM analysis using a GBMM (**Fig.**  
90 **1**). In comparison to state-of-the-art methods, we evaluate the calibration of PIP through  
91 simulations with various genetic architecture settings. We then compare the performance of  
92 identifying causal variants, with respect to mapping precision, credible set size, replication rate  
93 of discovery in an independent sample, and out-of-sample prediction using fine-mapped variants.  
94 Moreover, we develop a LD-based method to construct local credible sets (LCSs), where a  $\alpha$ -LCS  
95 represents a minimal set of SNPs in high LD that capture a causal variant with a posterior  
96 probability of  $\alpha$ , and estimate the proportion of SNP-based heritability explained by LCSs. To  
97 characterise the overall fine-mapping power in the current study, we propose a concept of global  
98 credible sets (GCSs), with a  $\alpha$ -GCS representing a minimal set of genome-wide SNPs that capture  
99  $\alpha\%$  of all causal variants for the trait. Furthermore, leveraging the genetic architecture estimated  
100 from SBayesRC, we develop a method to predict the power of fine-mapping and variance  
101 explained by the identified variants in prospective studies. With this method, we can estimate the  
102 minimal sample size required for identifying a desired proportion of causal variants or those  
103 variants explaining a desired proportion of the SNP-based heritability ( $h_{SNP}^2$ ). Finally, we apply

104 SBayesRC to the UK Biobank (UKB) data with 13 million SNPs to identify putative causal variants  
105 for 599 complex traits and diseases and compare the fine-mapping results using 48 well-powered  
106 traits from 6 categories.

107

## 108 **Results**

### 109 **Method overview**

110 We selected SBayesRC as the GBMM for GWFM (**Fig. 1**), as it has been shown to outperform other  
111 GBMMs in polygenic prediction<sup>27</sup>. SBayesRC is a hierarchical multi-component mixture model,  
112 where LD between SNPs is better modelled by matrix factorisation and functional genomic  
113 annotations are fitted jointly with the summary statistics in a unified computational framework  
114 (**Methods**). To optimize its performance for fine-mapping, we implemented an algorithm to  
115 automatically determine the number of mixture components in the model (**Methods**). In contrast  
116 to the existing fine-mapping methods, we fit all SNPs simultaneously and employed MCMC  
117 sampling to obtain the joint posterior distribution of model parameters and PIPs  
118 (**Supplementary Table 1**). In each MCMC iteration, we sampled a dummy variable for each SNP  
119 to indicate whether the SNP had a nonzero effect, conditional on the effects of other SNPs. After  
120 MCMC sampling, PIP was calculated as the frequency with which the SNP had nonzero effects  
121 across the iterations (**Methods**).

122

123 A high PIP value provides evidence of a causal variant. However, a causal variant may not have a  
124 high PIP value if it is in strong LD with other SNPs. For example, if the causal variant is in perfect  
125 LD with another SNP, then the PIP is expected to be 0.5 for each variant, regardless of the sample  
126 size. Therefore, the CS concept has been introduced to capture causal variants in strong LD with  
127 non-causal SNPs<sup>9,33</sup>. It is common to consider CS for SNPs that are close in physical distance, such  
128 as within a 100kb window<sup>34,35</sup>. However, we reason that this approach will miss causal variants  
129 with SNPs in long-range LD, and therefore proposed a new method to construct LCS based on LD  
130 between SNPs (**Methods**). Starting from the SNP with the largest PIP, we aimed to construct a  $\alpha$ -  
131 LCS for each “free” SNP (SNP that has not been included in any LCSs), by first selecting other “free”  
132 SNPs in high LD ( $r^2 > 0.5$ ) and then summing over their PIPs in a decreasing order until the sum  
133 is at least  $\alpha$  (a common strategy used in the literature<sup>11,12</sup>). To avoid having too many SNPs with  
134 small PIPs in the LCS, we calculated the posterior  $h_{SNP}^2$  enrichment probability (PEP), where PEP  
135 is the probability that the focal LCS explains more  $h_{SNP}^2$  than a random set of SNPs with the same  
136 size. The  $\alpha$ -LCS was eventually reported if its PEP was greater than 0.7.

137

138 In addition to LCS, we proposed another type of CS, GCS. Given the estimated number of causal  
139 variants from GBMM ( $m_c$ ), a  $\alpha$ -GCS was computed as the cumulative sum of decreasingly ranked

140 PIPs that is greater than  $\alpha \times m_c$ . It can be shown that a  $\alpha$ -GCS is expected to cover  $\alpha\%$  of all causal  
141 variants for the trait (**Methods**), with the size of  $\alpha$ -GCS reflecting the power of identifying the  
142 causal variants given the data (the higher the power, the smaller the  $\alpha$ -GCS size). Moreover, from  
143 the MCMC samples of SNP effects, we estimated the proportion of  $h_{SNP}^2$  explained by the LCSs and  
144 GCS (**Methods**).

145

146 Based on  $m_c$  and the distribution of causal effect sizes estimated from GBMM, we developed a  
147 method to predict the power and the proportion of  $h_{SNP}^2$  explained by the fine-mapped variants,  
148 given a sample size (**Methods** and **Supplementary Note**). This method allows us to estimate the  
149 minimal sample size required to achieve a desired power of identifying all causal variants or  
150 identifying the causal variants that explain a desired proportion of  $h_{SNP}^2$  of the trait, using the  
151 ancestry-specific fine-mapping result. Our method to predict fine-mapping power is analytically  
152 tractable and has been implemented in a publicly available online tool  
153 (<https://sbayes.pctgplots.cloud.edu.au/shiny/power/>).

154

155 We compared SBayesRC to several state-of-the-art fine-mapping methods, including FINEMAP<sup>12</sup>,  
156 SuSiE<sup>11</sup>, FINEMAP-inf<sup>13</sup>, SuSiE-inf<sup>7</sup>, and PolyFun+SuSiE<sup>19</sup>, as well as another GBMM, SBayesC (i.e.,  
157 two-component SBayesR<sup>24</sup>). All these methods assume a point-normal mixture prior for the SNP  
158 effects (**Methods** and **Supplementary Table 1**). A full list of acronyms used in this study can be  
159 found in **Supplementary Table 2**.

160

### 161 **Calibration of fine-mapping methods under various genetic architectures**

162 We performed extensive genome-wide simulations to calibrate different fine-mapping methods  
163 under various genetic architectures, using 100,000 individuals with ~1 million HapMap3 SNPs  
164 from the UKB<sup>36</sup>. We started by simulating a sparse genetic architecture, where 1% SNPs were  
165 randomly chosen as causal variants, with their effects sampled from a normal distribution,  
166 contributing 50% of the phenotypic variance. In this simulation, the data-generative model is  
167 consistent with the model used in SBayesC as well as the local fine-mapping methods in  
168 comparison. To challenge these methods, we simulated additional two complex genetic  
169 architectures (**Methods**). One was a large-effects architecture, where 10 random causal variants  
170 contributed 10% of the phenotypic variance and the remaining causal variants contributed 40%.  
171 Another complex genetic architecture was based on the sparse architecture but allowed for  
172 extensive LD between causal variants and SNP markers. This was achieved by sampling the causal  
173 variants only from SNPs in the high LD and high minor allele frequency (MAF) group, and  
174 therefore referred to as LD-and-MAF-stratified (LDMS) architecture. To calibrate each fine-

175 mapping method, we evaluated how well the reported PIPs are consistent with the actual fraction  
176 of causal variants, i.e., the true discovery rate (TDR).

177

178 Results showed that overall, the GWFM methods had the best calibration, the enhanced region-  
179 specific methods with an infinitesimal effect (i.e., FINEMAP-inf and SuSiE-inf) the second, and the  
180 standard region-specific methods (i.e., FINEMAP and SuSiE) the worst (**Fig. 2**). Under the sparse  
181 genetic architecture, PIPs from SBayesRC/SBayesC were in strong concordance with the TDR  
182 across its full spectrum (**Fig. 2a**). The concordance was reasonably good for SuSiE-inf and  
183 FINEMAP-inf, although with a trend of deflation in SNPs with low PIP, whereas for SuSiE and  
184 FINEMAP, even in SNPs with high PIPs, a notable inflation was observed, indicating a lack of  
185 control of FDR (=1-TDR) (**Fig. 2b-c**). When the large-effects or LDMS architecture was used, the  
186 assumption in the point-normal BMM was violated in a way that the causal effects did not come  
187 from a single normal distribution or that the causal variants were not randomly distributed  
188 across the genome. Consequently, PIPs from the point-normal BMM were no longer accurately  
189 tracking the true probabilities of causality. When the LDMS architecture was used, the FDR was  
190 even more poorly controlled in these methods (**Fig. 2d-i**). However, when SBayesRC was used,  
191 with LD and MAF bins as annotations, the strong concordance between PIP and TDR held in  
192 various architectures, although none of these architectures matched exactly with the analytic  
193 model assumed in SBayesRC.

194

195 In conclusion, the region-specific fine-mapping methods tended to have inflated FDR when the  
196 model assumptions were not met. In contrast, SBayesRC produced robust PIPs that were well  
197 calibrated under various genetic architectures.

198

### 199 **Local and global credible sets**

200 In addition to individual SNP PIP, CS is another critical statistic in fine-mapping. Here, we  
201 assessed the performance of SBayesRC in identifying LCS and GCS. For each LD block, we  
202 computed an  $\alpha$ -LCS that contains at least a causal variant with a probability of  $\alpha$  and is enriched  
203 in  $h_{SNP}^2$  (PEP > 0.7). We first evaluated the true discovery rate for identifying LCS, defined as the  
204 actual fraction of the LCS with at least a causal variant. The simulation result showed that the  
205 SBayesRC has a similar TDR to SuSiE-inf, which had the best PIP calibration among the region-  
206 specific fine-mapping methods (**Fig. S1a-c**). However, SBayesRC was significantly more powerful  
207 (**Fig. 3a-c**) and had a remarkably smaller LCS size than SuSiE-inf at the same  $\alpha$  threshold (**Fig.**

208 **3d-f)**. For instance, when  $\alpha=0.9$ , SBayesRC outperformed SuSiE-inf by up to 221% improvement  
209 in power and 41% reduction in LCS size across the three genetic architectures.

210

211 The  $\alpha$ -GCS is expected to cover  $\alpha$  proportion of the causal variants across the genome (**Methods**).  
212 Under various simulation scenarios, our GCS accurately represented the true proportion of causal  
213 variants (**Fig. S2a-c**), in contrast to the significant deflation observed with SBayesC (**Fig. S2a-c**).  
214 Furthermore, we observe a good agreement between estimated and observed power at any given  
215 PIP threshold from SBayesRC (**Fig. S2d-f**). Additionally, SBayesRC gave an unbiased estimate for  
216 the proportion of  $h_{SNP}^2$  explained by the GCS SNPs, regardless of the given  $\alpha$  value, under various  
217 scenarios (**Fig. S2g-i**).

218

### 219 **Improved mapping precision for identifying causal variants**

220 Our simulation results have shown that SBayesRC had the best calibration even under the  
221 architecture that matched with the assumed model for the region-specific fine-mapping methods.  
222 We next quantified the mapping precision of these methods. The mapping precision was defined  
223 as the distance of the identified variant that passed a given PIP threshold to the nearest causal  
224 variant. Hence, the smaller the distance, the higher the mapping precision, e.g., the distance is  
225 zero if the causal variant itself is identified. Results from the sparse architecture simulation  
226 showed that 97.8% of SBayesRC identified SNPs with PIP > 0.9 were the causal variants, and 99%  
227 significant SNPs were located within 16.4kb distance to the causal variants (**Fig. 4a**). With the  
228 same PIP threshold, 95.5% and 94.3% of SuSiE-inf and FINEMAP-inf identified SNPs were the  
229 causal variants, slightly higher than that of 95.3% and 94.0% from SuSiE and FINEMAP, with 99%  
230 significant SNPs located within 25.8kb (SuSiE-inf) and 31.3kb (FINEMAP-inf) to the causal  
231 variants, compared to that of 32.7kb and 36.7kb for SuSiE and FINEMAP, respectively. In  
232 conclusion, given a PIP threshold of 0.9, SBayesRC led to an at least 2% increase in TDR and a 64%  
233 (16.4kb/25.8kb) reduction in the distance to the causal variants, both indicating improved  
234 mapping precision compared to the existing methods. We also ran a LD block-wise SBayesC  
235 analysis, with model parameters estimated from each region separately. Our result showed that  
236 the mapping precision remained notable higher than the competing region-specific fine-mapping  
237 methods (**Fig. S3**).

238

239 In the simulation with large-effects architecture, the mapping precision for all methods decreased  
240 due to the decrease of average per-SNP heritability (from 0.5/10,000 to 0.4/9,990). However,  
241 SBayesRC still had the highest precision among all methods (**Fig. 4b**). In the simulation with  
242 LDMS architecture, SBayesRC demonstrated a substantially higher mapping precision than the  
243 other methods (**Fig. 4c**), likely because SBayesRC allowed the model to weigh SNPs differentially



244 based on their LD and MAF property so that the causal variants were better identified.  
245 Furthermore, we compared SBayesRC to Polyfun+SuSiE<sup>19</sup>, which is a stepwise method that  
246 accounts for the effect size stratification (by LD and MAF annotations) through a prior estimated  
247 from stratified LD score regression (S-LDSC)<sup>37,38</sup>. Indeed, Polyfun+SuSiE improved the mapping  
248 precision compared to the region-specific methods, but was still significantly inferior to  
249 SBayesRC (**Fig. 4c**). These simulation results suggested that SBayesRC is a reliable method for  
250 GWFM and can substantially improve the mapping precision of identifying causal variants.

251

### 252 **Improved replication rate of identification with less bias in estimation**

253 In real data analysis, direct evaluation of mapping precision is not feasible, because which  
254 variants have causal effects on a trait are often unknown. Alternatively, we can evaluate the  
255 replication rate of the identified variants using an independent sample<sup>13</sup>. Here, we define the  
256 replication rate as the proportion of variants with a significant PIP (e.g.,  $PIP > 0.9$ ) from the GWAS  
257 sample to be repeatedly identified in an independent (replication) sample with the same or a  
258 smaller PIP threshold. It is expected that the method that identifies most causal variants from the  
259 GWAS sample will have the highest replication rate, as the false positives are unlikely to be  
260 replicated.

261

262 We performed simulations using the UKB samples of European ancestry and split samples into  
263 independent datasets for discovery and replication. Putative causal variants were identified at  
264 the PIP threshold of 0.9 in the GWAS data ( $n=100,000$ ). We then quantified the replication rate of  
265 the putative causal variants at different significance thresholds in two replication datasets  
266 ( $n=100,000$  and  $200,000$ ). Using SBayesRC, roughly 33% of identified SNPs can be replicated at  
267  $PIP > 0.9$  when replication  $n = 100,000$ , and the replication rate increased to 71% when the  
268 replication sample size was doubled (**Fig. 4d**). It may seem counter-intuitive that only a fraction  
269 of SNPs was replicated despite using the same PIP threshold of 0.9 in both the discovery and  
270 replication datasets. This discrepancy is because there exists a sampling variation in the causal  
271 variants identified from distinct samples. As expected, the replication rate increased when using  
272 a lower threshold for replication, e.g., with  $PIP > 0.1$ , 79.6% of the identified SNPs can be  
273 replicated when replication  $n=100,000$ . Compared to other methods, SBayesRC demonstrated  
274 significantly higher replication rate at each of the PIP thresholds, while differences among the  
275 other four methods were small. We also quantified the replication rate in the reverse case where  
276 the GWAS sample size was 200,000 but the replication sample size was only 100,000, to mimic  
277 the reality that the sample size of replication data is often much smaller than that of discovery. In  
278 this scenario, we found that 19% of the identified SNPs can be replicated at  $PIP > 0.9$  using

279 SBayesRC, and the replication rate of SBayesRC remains significantly higher than that of other  
280 methods at each PIP threshold (**Fig. S4a**).

281

282 We then assessed the replication rate in the UKB height by constructing different discovery and  
283 replication datasets as in the simulation. The results were consistent with the observations from  
284 the simulation study (**Fig. 4e** and **Fig. S4b**). Compared to the region-specific methods, SBayesRC  
285 improved the replication rate by 11.3% (compared to FINEMAP) and by 1.2% (compared to  
286 SuSiE-inf) at PIP > 0.9 when replication  $n=100,000$ , and improved the replication rate by 19%  
287 (compared to FINEMAP) and by 3.5% (compared to SuSiE-inf) when replication sample size was  
288 doubled.

289

290 Moreover, we examined the bias in effect size estimates of putative causal variants identified from  
291 fine-mapping, through regressing their marginal effect sizes estimated from the replication  
292 samples on the joint effect sizes estimated from the GWAS sample (the regression slope is  
293 expected to be one for an unbiased estimation). In the simulation and UKB height analyses, the  
294 regression slope from SBayesRC was 0.978 and 0.974, respectively, superior to all the other  
295 methods (**Fig. 4f-g**), likely due to the genetic architecture was estimated simultaneously in  
296 SBayesRC but was preset or estimated locally in other fine-mapping methods.

297

298 These analyses suggested that the identified SNPs from SBayesRC are more likely to be causal  
299 because of the relatively high replication rate in independent samples and the negligible bias in  
300 effect size estimation, compared to the other methods.

301

### 302 **Improved prediction accuracy using fine-mapped variants**

303 Another approach to evaluate the results of fine-mapping is to conduct an out-of-sample  
304 prediction using the fine-mapped variants. Since all the Bayesian methods used in this study  
305 provide the posterior mean of SNP effects, we computed polygenic scores (PGS) based on the  
306 identified variants from each of the methods and evaluated the prediction accuracy in a validation  
307 sample. We split the 100K samples into 95K training samples to perform the fine-mapping  
308 analysis using all these Bayesian methods and predicted the phenotype for 5K independent  
309 individuals as validation samples. We found that overall, SBayesRC had a higher prediction  
310 accuracy compared to the other methods, outperforming them by at least ~17% at a PIP  
311 threshold of 0.9, with a relatively smaller number of SNPs included in the predictor (**Fig. 5a**). This  
312 is consistent with the result that SBayesRC resulted in a lower FDR than the other methods (**Fig.**  
313 **2a**).

314

315 We further compared the performance of these methods by trans-ancestry prediction in real  
316 traits. Specifically, we used the fine-mapped variants and estimated posterior effect sizes  
317 obtained from the UKB individuals of the European (EUR) ancestry to predict the phenotypes in  
318 three other ancestries in UKB: African (AFR), East Asian (EAS) and South Asian (SAS). We selected  
319 6 complex traits that had at least 50 identified SNPs at a PIP threshold of 0.9. We compared the  
320 performance of trans-ancestry prediction between SBayesRC and SuSiE-inf, because SuSiE-inf has  
321 exhibited a superior performance compared to the others. The result showed that compared to  
322 SuSiE-inf, SBayesRC improved the trans-ancestry prediction accuracy using fine-mapped variants,  
323 with a nearly 10-fold increase in the mean relative prediction  $R^2$  ( $\frac{R^2_{\text{SBayesRC}} - R^2_{\text{SuSiE-inf}}}{R^2_{\text{SuSiE-inf}}}$ ) across traits  
324 and ancestries (**Fig. 5b**). We further compared the performance of SBayesRC and SuSiE-inf for  
325 trans-ancestry prediction using the identified credible set SNPs. Similar to the comparison result  
326 based on fine-mapped variants, SBayesRC improved the trans-ancestry prediction accuracy  
327 based on the SNPs in the 90-LCS (**Fig. S5**; 1.7-fold increase on average). Since it is parsimonious  
328 to assume that the common causal variants and their effect sizes are mostly shared between  
329 ancestries<sup>39,40</sup>, we expect to observe a strong concordance in prediction accuracy between EUR  
330 and other ancestries using putative causal variants identified from the EUR sample with high  
331 confidence. To investigate this, we quantified the transferability of fine-mapped SNPs by  
332 computing the ratio of per-SNP prediction accuracy in a hold-out EUR sample to that in a different  
333 ancestry. The result showed that on average this relative prediction accuracy of SNP increases  
334 with its PIP calculated in the EUR GWAS sample (**Fig. 5c**). These results suggested that SBayesRC  
335 has higher power of fine-mapping and higher accuracy of variant effect estimation.

336

### 337 **Prediction of fine-mapping power and variance explained**

338 As a unique feature of the GWFM approach, the genetic architecture estimated from SBayesRC  
339 provides information to predict the proportion of causal variants identified from fine-mapping  
340 (power) and the proportion of  $h^2_{\text{SNP}}$  explained by these variants (PHE) for future studies  
341 (**Methods** and **Supplementary Note**). To evaluate our approach, we computed the predicted  
342 values of power and PHE at a spectrum of GWAS sample sizes and projected the outcome of fine-  
343 mapping using SBayesRC onto the prediction using data from the simulated trait with sparse  
344 architecture, height<sup>36</sup>, high density lipoprotein (HDL), schizophrenia (SCZ)<sup>41</sup>, and Crohn's Disease  
345 (CD)<sup>42</sup>. These traits were selected to represent different genetic architectures (**Fig. 6a-c**). Despite  
346 some variations across traits, the outcomes from the fine-mapping analyses were overall  
347 consistent with the theoretical predictions (**Fig. 6d,e**). While our theoretical prediction does not

348 model LD between SNPs, the extent to which the observed values were consistent with the  
349 predicted suggests that LD had been effectively, albeit not perfectly, accounted for by our LCSs.

350

351 Take SCZ for example. Using the latest GWAS summary statistics from the psychiatric genomics  
352 consortium dataset<sup>41</sup>, we identified 13 SNPs and 222 credible sets, collectively explaining 3.9%  
353 of  $h_{SNP}^2$  at the liability scale<sup>43</sup>. These estimates are highly consistent with our theoretical  
354 prediction given the 53,386 cases and 77,258 controls in their study<sup>41</sup>, which is equivalent to a  
355 sample size of 228,810 on the liability scale (ref<sup>44</sup>; **Methods**). For a prospective study using  
356 SBayesRC, we predict that ~180k cases would be required to fine-map 1,000 common causal  
357 variants (estimated to be 1.2% of all common causal variants), assuming an equal number of  
358 controls and a population prevalence of 0.01 (**Methods**), collectively accounting for about 20%  
359 of  $h_{SNP}^2$  (**Fig. 6**). With ~550k cases under the same assumption, we will be able to identify 10%  
360 causal variants explaining 50% of  $h_{SNP}^2$  in SCZ. To fine-map variants accounting for 80% of  $h_{SNP}^2$ ,  
361 it was estimated to require 1.4 million cases.

362

### 363 **Genome-wide fine-mapping in complex traits from UK Biobank**

364 We applied GWFM with SBayesRC to 599 complex traits (597 from the UKB) and developed an  
365 online resource to query these fine-mapping results (see Data Availability; **Supplementary**  
366 **Table 3**). We selected these 598 UKB traits based on z-score > 4 and high confidence for  
367 heritability estimates using LD score regression (<https://zenodo.org/records/7186871>). To  
368 better capture the causal variants, we used 13 million imputed SNPs with functional genomic  
369 annotations from Finucane et al.<sup>37</sup>. Here, we focus on discussing the results for 48 complex traits  
370 that had sufficient power, including SCZ, CD<sup>41,42</sup> and 46 UKB traits measured in the European  
371 ancestry inferred individuals (**Methods**). At the PIP significance threshold of 0.9, we identified  
372 2,868 SNPs associated with 48 complex traits, 1,641 of which were not identified by LD clumping,  
373 and 22,803 0.9-LCSs with an average size of 8.7 SNPs. On average across these 48 traits, we  
374 estimated that although these fine-mapped variants and LCSs only captured 0.75% of the causal  
375 variants, they accounted for 17.4% of the  $h_{SNP}^2$ .

376

377 Given the estimated genetic architecture for these 48 traits, we applied our theoretical prediction  
378 approach to predict the power of prospective GWAS studies. With a GWAS sample size of 2 million  
379 individuals, we predict that the average power is 9.5% (**Fig. 7a**) and average PHE is 54.1% (**Fig.**  
380 **7b**). The predicted values varied substantially between trait groups. Blood cell traits had both the  
381 highest power (29.7%) and highest expected proportion of  $h_{SNP}^2$  explained (86.9%), while  
382 cognitive traits have the smallest power (16.9%) and smallest expected proportion of genetic  
383 variance explained (63.1%). To achieve a PHE of 50%, blood cell traits require a GWAS sample

384 size of only 1 million individuals, while cognitive traits necessitate a sample size of 5 million  
385 individuals, due to the differences in genetic architecture across complex traits. The required  
386 sample size increased to 3 million and 10 million for blood cell counts and cognitive traits,  
387 respectively, to achieve a PHE of 80% (**Fig. 7b**).

388  
389 The global credible set  $\alpha$ -GCS varied in the credible set size and PHE estimate across traits (**Fig.**  
390 **7c**). On average, the 0.1-GCS, i.e., covering 10% of causal variants, consisted of 1% of the genome-  
391 wide SNPs, which explained 31.8% of the  $h_{SNP}^2$  (**Fig. 7d**). Among the analysed complex traits,  
392 diseases had the largest GCS sets, requiring 1.9% genome-wide common SNPs to cover 10%  
393 common causal variants. In contrast, blood cell traits had the smallest GCS, requiring merely 0.21%  
394 genome-wide common SNPs to cover 10% common causal variants. Interestingly, the 0.1-GCS for  
395 blood cell traits explained 44.3% of the total genetic variance, compared to 20.8% explained by  
396 the GCS for cognitive traits, highlighting the less polygenic genetic architecture of blood cell traits.

397  
398 Over the 48 complex traits, the number of fine-mapped variants from SBayesRC was highly  
399 correlated with the number of identified GWAS loci (**Fig. S6**), ranging from 1 to 489, with an  
400 average of 86.2 across complex traits (**Fig. S7**). Compared to the genome-wide SNPs and GWAS  
401 identified SNPs after LD clumping, the 2,868 putative causal variants had a significant  
402 overrepresentation in functional genomic regions included in the functional genomic  
403 annotations<sup>37</sup>, such as coding, promoter, and enhancer regions, and were significantly depleted  
404 in repressed regions (**Fig. 8a**), suggesting the importance of functional annotations. Of these  
405 variants, 651 (22.8%) were in association with more than one complex trait, highlighting the  
406 prevalence of pleiotropy in human genome. Moreover, the number of traits that the variant had  
407 pleiotropic effects decreased with its minor allele frequency (**Fig. S8**), consistent with that highly  
408 pleiotropic variants would be expected to be removed from the population or kept at low  
409 frequencies due to natural selection<sup>45</sup>.

410

#### 411 **Functional annotations helped pinpoint the putative causal variants**

412 One notable example is a variant (rs1421085) at the FTO locus, which was identified to be a  
413 putative causal variant using SBayesRC for body mass index (BMI), body fat percentage (BFP),  
414 hip circumference (HC) and waist circumference (WC). It has been previously validated that this  
415 variant plays a causal role in adipocyte thermogenesis regulation<sup>46</sup>. Unlike the results from the  
416 standard GWAS where many SNPs in the FTO locus exhibited a signal at genome-wide significance  
417 level, our analysis showed that only the known causal variant (rs1421085) was significantly (PIP >  
418 0.9) associated with BMI (**Fig. 8b**). In contrast, applying other methods (SBayesR and SuSiE-inf)  
419 without functional annotations to the locus identified the GWAS lead SNP instead, underscoring

420 the importance of incorporating functional annotations. In particular, the annotations of  
421 conservation across species, especially primates, helped distinguish the causal variant from the  
422 GWAS lead SNP (**Fig. 8c**). Moreover, a secondary signal rs76488452 (PIP=0.85) was identified by  
423 SBayesRC, which has not been previously reported but was included in a local credible set of 5  
424 SNPs in both SBayesR and SuSiE-inf (**Fig. S9**). We found this SNP resided in a conserved region in  
425 primates and was also significant in the COJO analysis (p-value =  $1.8 \times 10^{-17}$ ) conditional on the  
426 known causal variant. Notably, the secondary signal (rs76488452) was only nominally  
427 significantly in the GWAS marginal analysis (p-value =  $3.6 \times 10^{-4}$ ), whose trait-increasing allele was  
428 in negative LD ( $r=-0.16$ ) with that of the known causal variant, indicating that this SNP is likely to  
429 have a masked effect<sup>47</sup> (estimated masked effect size  $b_2 - r * b_1 = 0.02$ , consistent with the reported  
430 GWAS marginal effect size).

431

432 Another example is from the fine-mapping results for SCZ. We identified 13 SNPs at PIP > 0.9 for  
433 SCZ from the latest meta-analysis, 5 of which were the same SNPs that were identified using  
434 FINEMAP in their study<sup>41</sup>, and all the 8 SNPs identified by FINEMAP were included in our 0.9-  
435 LCSs. We recapitulated a missense variant (rs13107325) in *SLC39A8*, a gene highlighted in the  
436 latest SCZ analysis for its function in regulating dendritic spine density<sup>48,49</sup>. Furthermore, we  
437 identified a secondary variant at the same locus, located in important functional regions (**Fig. 8d-**  
438 **e**). Among the 5 novel fine-mapped SNPs that were not identified by FINEMAP with individual  
439 PIP, 3 were missense variants (**Fig. S10a-c**). We highlight rs11845184, which is located within  
440 *SECISBP2L* (**Fig. S10a**). *SECISBP2L* is highly expressed in brain-related tissues (**Fig. S11**),  
441 specifically in differentiating oligodendrocytes, where the SECISBP2L-DIO2-T3 pathway  
442 mediates the autonomous regulation of oligodendrocyte differentiation during myelin  
443 development<sup>50</sup>. Moreover, we identified novel putative causal variants for CD (**Supplementary**  
444 **Table 4**). Using SBayesRC, we fine-mapped 31 variants, of which 10 were missense variants, and  
445 all 3 variants identified in the previous study using the same data were recapitulated<sup>42</sup>. In  
446 addition, compared to a recent exome-wide association study for CD<sup>51</sup>, we identified 4 novel  
447 genes (*LACC1*, *SLAMF8*, *MAN2B2* and *GPR35*) with missense putative causal variants (**Fig. S12**).  
448 These results demonstrated the power of SBayesRC for identifying the plausible causal variants  
449 and provide a valuable resource for downstream analysis and functional validation.

450

## 451 Discussion

452 In this study, we comprehensively evaluated the performance of GWFM using SBayesRC by  
453 extensive simulation and real data analyses, compared with the existing fine-mapping methods  
454 that consider one genomic region at a time. Our results showed that both PIP and CS from  
455 SBayesRC were correctly calibrated under various genetic architectures, indicating well

456 controlled FDR. In contrast, the other methods produced mis-calibrated PIP and CS with inflated  
457 FDR, when the genetic architecture did not match the model assumption. While all fine-mapping  
458 methods gave a higher mapping precision than that from GWAS<sup>7</sup>, SBayesRC had the highest  
459 precision across genetic architecture scenarios. Furthermore, in both simulation and real trait  
460 analyses, SBayesRC showed significantly higher replication rate and prediction accuracy but less  
461 estimation bias in an independent sample using fine-mapped SNPs, compared with the other  
462 methods. In the real data analysis, we showed examples where SBayesRC pinpointed the putative  
463 causal variants that were missed by the other methods. All of these results indicate that SBayesRC,  
464 as a method for GWFM analysis, remarkably improves the identification of causal variants.

465  
466 We proposed a new LD-based method to compute LCSs and estimate their contribution to the  
467 SNP-based heritability. This method overcomes the limitation of existing window-based  
468 approaches that causal variants with SNPs in long-range LD would not be captured. In addition  
469 to LCSs, SBayesRC allows us to compute a GCS for the trait, which informed the power of  
470 identifying the causal variants and the  $h_{SNP}^2$  explained by the identified SNPs given the data. This  
471 computation requires an unbiased estimation on the total number of the causal variants, which  
472 can only be done when analysing all SNPs jointly in the model. The analysis of 48 complex traits  
473 showed that although as many as 22,803 variants or LCS were identified, they only captured 0.75%  
474 of all common causal variants and contributed 17.4% genetic variance, suggesting many causal  
475 variants with very small effects are yet to be discovered (**Fig. 7c,d**).

476  
477 We have provided a theoretical prediction of fine-mapping power given a sample size and the  
478 estimated genetic architecture (**Supplementary Note**). This is useful to inform the experimental  
479 design of future fine-mapping studies regarding the sample size required to identify a certain  
480 number of causal variants or those explaining a certain proportion of  $h_{SNP}^2$ . The robustness of our  
481 prediction approach is supported by projecting the outcomes of real data analyses to the  
482 landscape of predicted values. For height, based on the UKB data (n = 350k), we predicted that  
483 when the sample size increases to 5 million, the number of fine-mapping discoveries would be  
484 ~10,000 considering significant PIPs only or ~30,000 considering both significant PIPs and LCSs,  
485 explaining up to 95% of the genetic variance (**Fig. 6**). This prediction is consistent with the finding  
486 of a recent GWAS with 5 million individuals, which reported 12,111 independently significant  
487 SNPs identified from COJO accounting for nearly all of the common SNP-based heritability in  
488 height<sup>40</sup>.

489  
490 While the concept of credible set has evolved over time<sup>11,12,52</sup>, it is still common to focus on  
491 individual SNP PIP in the downstream analysis, probably because the CS include too many SNPs

492 to follow up. Our study provided important implications regarding this issue. First, CS may miss  
493 the true causal variant if not all possible causal variants are fitted in the model, underscoring the  
494 importance of considering all common SNPs in the fine-mapping analysis. Second, our GWFM  
495 approach can reduce the credible size, as shown in both simulation and real trait analysis (only  
496 ~8.7 SNPs per credible set), facilitating the consideration of CS in practice. Third, in the presence  
497 of complete LD between SNPs and the causal variants, the PIP of a causal variant may never be  
498 significant regardless of sample size, but leveraging functional genomic annotations may help  
499 distinguish causal from non-causal variants. In this sense, genomic annotations play a greater role  
500 than the increase of GWAS sample size.

501

502 The advantages of SBayesRC over the region-specific fine-mapping methods arise from the  
503 following aspects. First, SBayesRC involves a genome-wide analysis fitting all SNPs jointly.  
504 Compared to the region-specific analysis, genome-wide analysis accounts for long-range LD and  
505 utilises all SNPs to estimate the genetic architecture, thereby improving fine-mapping. Of note,  
506 even when the same LD blocks are used in both types of analyses, the latter is still superior  
507 because of the better estimation of genetic architecture parameters from genome-wide SNPs.  
508 Second, SBayesRC assumes a more realistic distribution of SNP effects through using MAF/LD  
509 groups along with other functional annotations. In addition, the impact of annotations on the SNP  
510 effect distribution is estimated within the same model, fostering a formal Bayesian learning  
511 process. The existing fine-mapping methods, however, either do not leverage annotation data or  
512 lack a unified framework for the joint analysis with GWAS data. Third, SBayesRC utilises MCMC  
513 sampling to estimate model parameters and PIPs, which is asymptotically exact. Both FINEMAP  
514 and FINEMAP-inf use shotgun stochastic search, while both SuSiE and SuSiE-inf use variational  
515 Bayes to compute the Bayes factors for the causal models and therefore the PIPs. It has been  
516 previously shown that MCMC sampling generally leads to a higher accuracy of capturing the  
517 posterior distribution than the other approximation approaches<sup>30</sup>. To further justify our choice  
518 of SBayesRC as the method for GWFM, we ran SBayesRC within each block separately and  
519 quantified the mapping precision. We found that the mapping precision decreased compared to  
520 the genome-wide SBayesRC but remained higher than the other methods (**Fig. S2**). For example,  
521 99% of SNPs identified by the region-specific SBayesRC were located within 23.1Kb to causal  
522 variants, compared to the number of 16.4Kb for the genome-wide SBayesRC and 25.8Kb for  
523 SuSiE-inf.

524

525 We note several limitations of this work. First, there are certainly more complicated scenarios  
526 about effect size distribution for causal variants that have not been investigated in our  
527 simulations. However, to our knowledge, SBayesRC is one of the most flexible models to



528 accommodate various scenarios because it assumes a multi-component Gaussian mixture, and  
529 we have further allowed the method to automatically choose the number of mixture components.  
530 Second, unlike an individual-level model where each PIP is calculated conditional on the effects  
531 from all other SNPs jointly, SBayesRC is a summary-level model where LD between LD blocks is  
532 ignored so that SNPs beyond the region contribute to the PIP only through the mixture  
533 distribution of SNP effects. Third, we only applied our method to the GWAS summary data from  
534 relatively homogenous populations (inferred European ancestry) and the robustness of the  
535 methods on GWAS data based on trans-ancestry meta-analyses is not investigated. Fourth,  
536 SBayesRC requires the LD information estimated from a cohort that matches with GWAS ancestry  
537 without substantial sampling variation. Fifth, to create the credible set, a threshold of 0.5 was  
538 arbitrarily chosen to define a set of SNPs in high LD. Latest methodological advancements in  
539 Bayesian hypothesis tests based on hierarchical clustering can be used to relax this condition<sup>53</sup>.  
540 Sixth, the prediction of mapping power is based on the genetic architecture estimates given a SNP  
541 set. However, the SNP set may change with the sample size (e.g., more common SNPs to be  
542 observed in a larger sample size), which may affect the polygenicity and SNP-based heritability.  
543 Despite these limitations, our study provides a robust and versatile GWFM framework for  
544 identifying causal variants, highlighting the advantages of this approach over existing region-  
545 specific fine-mapping methods. With its capacity to enhance mapping power in the current study  
546 and to predict mapping power for future studies, we believe GWFM using a state-of-the-art GBMM  
547 will become the preferred method for analysing complex traits.

## 548 **Methods**

### 549 **Ethics approval**

550 The University of Queensland Human Research Ethics Committee B (2011001173) provides  
551 approval for analysis of human genetic data used in this study on the high-performance cluster  
552 of the University of Queensland.

### 554 **Low-rank GBMM**

555 We used state-of-the-art GBMM that employed a low-rank model to improve computational  
556 efficiency and robustness<sup>27</sup>. As described below, the low-rank GBMM can be derived from the  
557 individual-level model. Consider a multiple linear regression of phenotypes on genotypes:

$$558 \quad \mathbf{y} = \mathbf{X}\boldsymbol{\beta} + \mathbf{e} \quad (1)$$

559 where  $\mathbf{y}$  is an  $n \times 1$  vector of complex trait phenotypes and  $\mathbf{X}$  is an  $n \times m$  matrix of mean-centred  
560 genotypes,  $\boldsymbol{\beta}$  is  $m \times 1$  vector of SNP effects on the trait, and  $\mathbf{e}$  is  $n \times 1$  vector of residuals with  
561  $\text{var}(\mathbf{e}) = \mathbf{I}\sigma_e^2$ . Let

$$562 \quad \mathbf{K} = \boldsymbol{\Lambda}^{-\frac{1}{2}}\mathbf{U}'\mathbf{X}'n^{-1} \quad (2)$$

563 where  $\boldsymbol{\Lambda}$  and  $\mathbf{U}$  are diagonal matrix of eigenvalues and matrix of eigenvectors for the LD  
564 correlation matrix  $\mathbf{R} = \mathbf{X}'\mathbf{X}/n$ , respectively. It follows that  $\mathbf{K}'\mathbf{K} = \mathbf{P}n^{-1}$ , where  $\mathbf{P}$  is the projection  
565 matrix of  $\mathbf{y}$  on the column space of  $\mathbf{X}$ , and  $\mathbf{K}\mathbf{K}' = \mathbf{I}n^{-1}$ . Multiplying both sides of Eq (2) by  $\mathbf{K}$  gives

$$566 \quad \mathbf{K}\mathbf{y} = \mathbf{K}\mathbf{X}\boldsymbol{\beta} + \mathbf{K}\mathbf{e} \quad (3)$$

567 or

$$568 \quad \mathbf{w} = \mathbf{Q}\boldsymbol{\beta} + \boldsymbol{\epsilon} \quad (4)$$

569 When only the top  $q$  principal components of  $\mathbf{R}$  are used, the dimension of  $\mathbf{w}$  is  $q \times 1$  and  $\mathbf{Q}$  is  
570  $q \times m$ . Since  $q \ll n$ , this model would have a substantially lower rank than Eq (1), improving the  
571 computational efficiency for the estimation of  $\boldsymbol{\beta}$ . With a recognition of  $\mathbf{b} = \mathbf{X}'\mathbf{y}/n$  is the GWAS  
572 marginal effect estimates,  $\mathbf{w}$  can be directly computed from the GWAS summary statistics. In  
573 practice, we compute  $\mathbf{w}$  and  $\mathbf{Q}$  within quasi-independent LD blocks in the human genome. With  
574 this low-rank model, we can estimate  $\boldsymbol{\beta}$  for all common variants jointly through considering  $\boldsymbol{\beta}$  as  
575 random effects. In addition, this model allows a direction estimation of the residual variance, as  
576  $\text{var}(\boldsymbol{\epsilon}) = \mathbf{I}\sigma_e^2n^{-1}$ , which can be used as a nuisance parameter to accommodate heterogeneity in  
577 the summary statistics and LD reference<sup>27</sup>.

578

### 579 **SBayesC and SBayesRC**

580 GBMMs are flexible in the specification of the prior distribution of SNP effects. In SBayesC, the  
581 prior for the effect size of variant  $j$  is,

$$582 \quad \beta_j \sim N(0, \sigma_{\beta}^2)\pi + \phi(1 - \pi) \quad (5)$$

583 where  $\sigma_\beta^2$  is the common variance across all the causal variants,  $\pi$  is the proportion of SNPs with  
 584 nonzero effects, and  $\phi$  is a point mass at zero. Both  $\sigma_\beta^2$  and  $\pi$  are considered as unknown, with a  
 585 scaled inverse chi-squared prior distribution and a uniform prior distribution, respectively<sup>27</sup>.

586  
 587 SBayesRC<sup>27</sup> is an extension of SBayesR<sup>24</sup>, which allows for a more realistic prior distribution of  
 588 SNP effects by assuming a multiple component mixture distribution

$$589 \beta_j \sim \sum_{k=1}^5 \pi_k N(0, \gamma_k \sigma_g^2) \quad (6)$$

590 where  $\boldsymbol{\gamma} = (\gamma_1, \gamma_2, \gamma_3, \gamma_4, \gamma_5)' = (0, 1 \times 10^{-5}, 1 \times 10^{-4}, 1 \times 10^{-3}, 1 \times 10^{-2})'$  are the prespecified  
 591 coefficients to constrain the variance in each effect size distribution with respect to the total  
 592 genetic variance ( $\sigma_g^2$ ), and  $\pi_k$  is the prior probability for the SNP effect belong to the  $k$ th  
 593 distribution. To further account for the stratification of causal variants and their effects regarding  
 594 functional annotations, SBayesRC assumes a SNP-specific prior probability of distribution  
 595 membership,  $\pi_{jk}$ , depending on the annotations at each SNP, through a generalised linear model.  
 596 Specifically,

$$597 f(\pi_{jk}) = \mu_k + \sum_{l=1}^c A_{jl} \alpha_{kl} \quad (7)$$

598 where  $f(\cdot)$  is the probit link function,  $\mu_k$  is the intercept,  $A_{jl}$  is the value of annotation  $l$  on SNP  $j$   
 599 (either binary or continuous annotations), and  $\alpha_{kl}$  is the effect of annotation  $l$  on the prior  
 600 probability of the SNP effect belonging to the  $k$ th distribution. Details of the method can be found  
 601 in ref<sup>27</sup>.

### 602 603 **Calculation of PIP**

604 We assessed the strength of joint association of each SNP using the posterior inclusion probability  
 605 (PIP), i.e., the probability of a SNP being included with a nonzero effect in the model, given the  
 606 data. Let  $\delta_j$  be the indicator variable for the distribution membership for SNP  $j$ , with  $\delta_j = 1$   
 607 indicating a null effect and  $\delta_j = 2, \dots, K$  indicating a nonnull component. We computed PIP for  
 608 SNP  $j$  as

$$609 \text{PIP}_j = 1 - \Pr(\delta_j = 1 | y) = 1 - \frac{f(y|\delta_j=1)\pi_1}{\sum_{k=1}^J f(y|\delta_j=k)\pi_k} \quad (8)$$

610 The likelihood function when  $\delta_j = 1$  are

$$611 f(y|\delta_j = 1) \propto \exp\left\{-\frac{y_c' y_c}{2\sigma_e^2}\right\} \quad (9)$$

612 where  $y_c$  is the adjusted  $y$  for all other effects except that for SNP  $j$ .

613 The likelihood function when  $\delta_j = k$  is

$$614 f(y|\delta_j = k) \propto \exp\left\{-\frac{y_c' y_c}{2\sigma_e^2}\right\} \lambda_k^{\frac{1}{2}} C_k^{-\frac{1}{2}} \exp\left\{\frac{r^2}{2C_k}\right\} \quad (10)$$

615 where  $\lambda_k = \frac{\sigma_e^2}{\gamma_k \sigma_g^2}$ ,  $C_k = n + \lambda_k$ ,  $r = X' y_c = X' e + n\beta$ . A full derivation of equation above can be  
616 found in the supplementary Note.

617

618 For all GBMM analyses in this study, we ran Markov chain Monte Carlo (MCMC) sampling for  
619 10,000 iterations with the first 2,000 samples as burn-in and we used the posterior mean over  
620 8,000 posterior samples to estimate  $\pi$  and PIPs.

621

### 622 **Automatic determination of mixture components**

623 The standard SBayesRC requires specification of the number of mixture components before the  
624 analysis. It has been shown that the performance of polygenic prediction is robust to the number  
625 of mixture components<sup>27</sup>. However, this may be a problem for fine-mapping if a small effect  
626 component is unnecessarily included, where null SNPs are fitted by chance to explain negligible  
627 variance. This is because these SNPs may affect the distribution of PIPs and cause a bias in the  
628 estimation of the number of causal variants. In this study, we have allowed the method to  
629 automatically determine the number of mixture components for SBayesRC. The procedure  
630 started with running SBayesRC using the default setting of five mixture components. After 500  
631 iterations of MCMC, the smallest component would be removed if the genetic variance explained  
632 by the SNPs in this component were less than half of that in the second smallest component. This  
633 procedure was repeated until no component was removed from the model. The rationale is that  
634 in most complex traits, due to the action of negative selection, most variation is attributed to  
635 variants with small effects<sup>31,32,54</sup>. Hence, if the smallest component is capturing true genetic effects,  
636 it should contribute to a significant proportion of variance, unlikely to be substantially lower than  
637 the second smallest component.

638

### 639 **Local and global credible sets**

640 Similar to prior work<sup>14</sup>, we defined the local credible set SNPs as the minimum set of SNPs that  
641 contains at least one causal variant with a probability of  $\alpha$ . To identify the  $\alpha$ -LCS, we ranked SNPs  
642 based on their PIPs and constructed candidate credible set for each “free” SNP which was not in  
643 any LCSs. For the focal SNP, the candidate credible set was created by including “free” SNPs in  
644 high LD ( $r^2 > 0.5$ ) with a focal SNP and computed the  $\alpha$ -LCS by summing over PIPs in a decreasing  
645 order until the sum is at least  $\alpha$ . This process was iteratively repeated until all SNPs were  
646 exhausted. For each  $\alpha$ -LCS, we calculated an LCS posterior SNP-heritability enrichment  
647 probability, where PEP is the probability that the focal LCS explains more  $h_{SNP}^2$  than a random set  
648 of SNPs with the same size. We reported all the 0.9-LCS with PEP  $> 0.7$  for each LD block. The true  
649 discovery rate was quantified as the proportion of identified  $\alpha$ -LCS containing at least one causal

650 variant, and the power was calculated as the proportion of simulated causal variants included in  
651 the identified  $\alpha$ -LCS.

652  
653 Analogous to the LCS, which identifies a set of SNPs that capture a causal variant with a  
654 probability of  $\alpha$ , the GCS identifies a set of SNPs that capture all causal variant with a probability  
655 of  $\alpha$ , which is equivalent to finding a set of SNPs that capture  $\alpha\%$  of the causal variants. We  
656 computed the  $\alpha$ -GCS as the cumulative sum of decreasingly ranked PIPs that was greater than  
657  $\alpha \times m_c$ , where  $m_c$  was the estimated number of causal variants from GBMM for the trait. The  $\alpha$ -  
658 GCS is expected to cover  $\alpha\%$  of all causal variants for the trait, i.e., the power of identifying the  
659 causal variants given the data (**Supplementary Note**).

660  
661 **Estimation of power and variance explained given the data**

662 For the identified SNPs using individual PIP or credible set, we estimated the power of identifying  
663 the causal variants given the data at a given threshold  $\alpha$ ,

664 
$$\text{TPR}_\alpha = \frac{\sum_j [\text{PIP}_j | \text{PIP}_j \geq \alpha]}{M\pi} \quad (11)$$

665 A formal derivation is given in the **Supplementary Note**.

666  
667 Moreover, we estimated the proportion of SNP-based heritability explained (PHE) by LCSs.  
668 Specifically, we computed PHE for a focal set ( $i$ ) of SNPs in each MCMC iteration using the sampled  
669 values of SNP effects,

670 
$$\text{PHE}_{mcmc_r, i} = \frac{\sum_j [\beta_{mcmc_r, j}^2 | j \in i]}{\sum_{m=1}^M [\beta_{mcmc_r, m}^2]} \quad (12)$$

671 where  $\beta_{mcmc_r, j}$  is the sampled effect for SNP  $j$  from MCMC iteration  $r$  in the scaled genotype unit.  
672 Finally, we computed the posterior mean across MCMC iterations as the estimate for  $\text{PHE}_i$ ,

673 
$$\text{PHE}_i = \frac{\sum_r \text{PHE}_{mcmc_r, i}}{L} \quad (13)$$

674 where  $L$  is the total number of MCMC iterations.

675  
676 **Prediction of power and variance explained for prospective studies**

677 We aim to predict the power of identifying a certain proportion of the causal variants in a  
678 prospective fine-mapping analysis, given a sample size ( $n$ ) and the genetic architecture of the trait,  
679 when PIP from a GBMM is used as the test statistic. As shown in the **Supplementary Note**,  
680 assuming that variance explained by the causal variant is  $v$ , the sampling distribution of PIP from  
681 the multi-component mixture model, e.g., SBayesRC, is

682 
$$\text{PIP} = 1 - \frac{1}{1 + \sum_{k=2}^5 A_k \exp\{B_k Z\}} \quad (14)$$

683 where  $A_k = \frac{\pi_k}{\pi_1} \lambda_k^{\frac{1}{2}} C_k^{-\frac{1}{2}}$  and  $B_k = \frac{n\sigma_e^2}{2C_k}$  are two constants given the genetic architecture parameters  
 684 ( $\boldsymbol{\pi}$  and  $h_{SNP}^2$ ), with  $\lambda_k = \frac{\sigma_e^2}{\gamma_k \sigma_g^2}$  and  $C_k = n + \lambda_k$ , and  $Z$  is a data-dependent random variable  
 685 following a non-central Chi-square distribution with the non-centrality parameter  $NCP = \frac{nv}{\sigma_e^2}$ :

$$686 \quad Z \sim \chi_1^2\left(\frac{nv}{\sigma_e^2}\right) \quad (15)$$

687 Given the threshold of PIP being  $\alpha$  for the hypothesis test, the power to detect this causal variant  
 688 can be calculated as

$$689 \quad Power_v = \Pr(PIP > \alpha|v) = \int_{\alpha}^1 f(PIP|v)dPIP \quad (16)$$

690 where  $f(PIP|v)$  is Eq (14) above. To compute the power for identifying any causal variant, we  
 691 integrated out  $v$  by

$$692 \quad Power = \int_{\alpha}^1 \int_0^{\infty} f(PIP|v)f(v)dv dPIP \quad (17)$$

693 where

$$694 \quad f(v) = f_{\beta}(v^2)v^{-\frac{1}{2}} \quad (18)$$

695 and  $f_{\beta}(\cdot)$  is the distribution of  $\beta$  estimated from the SBayesRC model.

696

697 Therefore, given a sample size, the expected number of causal variants identified from fine-  
 698 mapping is

$$699 \quad E[NCV] = m(1 - \pi_1) \times Power \quad (19)$$

700 The expected proportion of genetic variance explained by the fine-mapped variants is

$$701 \quad E[PHE] = m(1 - \pi_1)\sigma_g^{-2} \int_0^{\infty} Power_v \times vf(v)dv \quad (20)$$

702 Since it is computationally challenging to obtain an analytical solution, we opted to estimate these  
 703 quantities through Monte Carlo simulation (**Supplementary Note**).

704

### 705 **Disease sample size at the liability scale**

706 For diseases or binary traits, we converted the GWAS summary statistics from the linear mixed  
 707 model to the liability scale prior to running GBMM. Based on the method in Yang et al.<sup>44</sup>, we  
 708 estimated the sample size at the liability scale that gives an equivalent power to detect a locus  
 709 affecting a quantitative trait with the same properties,

$$710 \quad N_{eq} = \frac{i^2 v(1-v)N_{01}}{(1-K)^2} \quad (21)$$

711 where  $K$  is the disease prevalence,  $v$  is the sample prevalence,  $i = h/K$  with  $h$  being the height of  
 712 standard normal curve at the truncation point  $t = 1 - K$ , and  $N_{01}$  is the total number of cases and  
 713 controls. Given the z-score ( $z_j$ ) from the original GWAS summary data for SNP  $j$ , the marginal  
 714 effect and its standard error at the liability scale can be estimated as following ref<sup>55</sup>

715 
$$SE_j = \sqrt{\frac{1}{2p_j(1-p_j)(N_{eq}+z_j^2)}} \quad (22)$$

716 
$$b_j = z_j \times SE_j \quad (23)$$

717 where  $p_j$  is the minor allele frequency of the SNP.

718

719 The results from GBMM using the converted summary statistics will be directly comparable  
720 across traits regardless of the sample prevalence and the type of traits. In our prediction analysis  
721 of power, we compared results between diseases and quantitative traits based on the equivalent  
722 sample size estimated from Eq (23). Similarly, to estimate the number of cases required, in a case-  
723 control study with equivalent number of controls, to achieve a certain power, we rearranged the  
724 same equation so that

725 
$$N_{cases} = \frac{1(1-K)^2 N_{eq}}{2i^2v(1-v)} \quad (24)$$

726

### 727 **Simulations based on imputed genotype data from the UK Biobank**

728 To evaluate the performance of GBMM, we ran simulations using the imputed genotype data from  
729 the UK Biobank after quality controls (QC). In this study, we selected 300,000 unrelated  
730 individuals and included ~1.2 million HapMap3 SNPs with MAF > 0.01, Hardy-Weinberg  
731 equilibrium test  $P > 1 \times 10^{-6}$ , genotyping rate > 0.95, and imputation information score > 0.8 for  
732 simulations.

733

734 We randomly sampled  $m_c = 10,000$  casual variants from the genome for 100,000 individuals and  
735 simulated complex trait phenotypes based on the following model:

736 
$$\mathbf{y} = \mathbf{X}\boldsymbol{\beta} + \mathbf{e} \quad (25)$$

737 where  $\mathbf{X}$  is the genotype matrix for the causal variants,  $\beta_i \sim N(0, h^2/m_c)$  and  $e_j \sim N(0, var(\mathbf{X}\boldsymbol{\beta})/$   
738  $(1/h^2 - 1))$  with  $h^2 = 0.5$  being the proportion of phenotypic variance explained by all the  
739 causal variants. To check the robustness of GBMM, we also ran simulations under various settings.  
740 For simulations under LD-MAF stratification model, we partitioned all the genome-wide SNPs  
741 into four LD and MAF groups (by their median values) and only sampled the 10,000 causal  
742 variants in the high LD and high MAF group. For the major gene model simulation, we separated  
743 the sampling of effect size for causal variants from two distributions, i.e., 10 random SNPs with  
744 effects from  $N(0, 0.2 * h^2/10)$  and the rest SNPs with effects from  $N(0, 0.8 * h^2/9990)$ .

745

746 We ran a standard GWAS using the genotypes with the simulated phenotypes under different  
747 settings. We then used the GWAS summary data to perform GBMM (SBayesRC<sup>27</sup> and SBayesC<sup>24</sup>)  
748 implemented in GCTB, SuSiE<sup>11</sup>, FINEMAP<sup>12</sup>, SuSiE-inf<sup>13</sup>, FINEMAP-inf<sup>13</sup> and PolyFun-S<sup>19</sup> to detect

749 fine-mapped variants and compute corresponding PIPs and effect sizes. We used imputed  
750 genotypes from 10,000 random samples from UK Biobank as the LD reference in this study. We  
751 repeated the whole process 100 times and then quantified the true discovery rate, mapping  
752 precision and replication rate for each method. The mapping precision was computed as the  
753 physical distance between the identified SNPs and nearest causal variants.

754

### 755 **Real data analysis**

756 We analysed 598 UK Biobank complex traits GWAS summary data from Neale's lab (**Data**  
757 **Availability**) and the schizophrenia<sup>41</sup> and Crohn's disease<sup>42</sup> GWAS summary data. We selected  
758 these 598 traits with z-score > 4 and high confidence for heritability estimates using LD score  
759 regression. We used the annotations from baseline model BaseLineLD v2.2<sup>38</sup> and extract the  
760 imputed SNPs with MAF > 0.001 and that are in common with the annotations, leading to  
761 13,065,104 imputed SNPs passed the quality control. We used 10,000 random samples from the  
762 UK Biobank as the LD reference to run the SBayesRC and other region-specific fine-mapping  
763 analysis. We further extracted 48 well-powered traits with relatively large sample size (n > 100,  
764 000), high heritability ( $h^2 > 0.1$ ) and at least a fine-mapped SNP at PIP > 0.9.

765

766 For the polygenic score prediction analysis using fine-mapped variants only, we performed  
767 quality control for the imputed genotype data provided by the UKB analysis team<sup>36</sup>. We kept SNPs  
768 with MAF > 0.01, Hardy-Weinberg Equilibrium test  $P > 10^{-10}$ , imputation info score > 0.6 within  
769 each ancestry samples. We removed samples with mismatched sex information, samples  
770 withdrawn from participation and cryptic related samples following ref<sup>27</sup>. We separate the final  
771 UKB dataset into 4 ancestries, European (EUR, N= 347,800), East Asian (EAS, N=2,252), South  
772 Asian (SAS, N=9,436) and African (AFR, N=7,006). The phenotypes with continuous values were  
773 filtered within the range of mean +/- 7SD and then rank-based inverse-normal transformed  
774 within each ancestry and sex group. The GWAS were performed using PLINK2 software<sup>5</sup> with sex,  
775 age and first 10 principal component as covariates. Linear regression was used for continuous  
776 traits and logistic regression for binary traits.

777

### 778 **Supplementary Information**

779 Supplementary data include 12 supplementary figures, 4 supplementary table and a  
780 supplementary note.

781

### 782 **Data Availability**

783 Our SBayesRC-enabled genome-wide fine-mapping results for 599 complex traits are available at  
784 link (<https://sbayes.pctplots.cloud.edu.au/data/SBayesRC/share/Finemap/v1.0/>). The UK



785 Biobank data are available through formal application to the UK Biobank  
786 (<http://www.ukbiobank.ac.uk>). The GWAS summary data for 598 complex traits in UK Biobank  
787 are from <http://www.nealelab.is/uk-biobank/>. All the other datasets used in this study are  
788 available in the public domain.

789

### 790 **Code Availability**

791 Summary-data-based genome-wide Bayesian mixture models are implemented in a public  
792 available software GCTB at <https://cnsgenomics.com/software/gctb/#Download>. Methods to  
793 compute LCS and GCS have also been implemented in GCTB  
794 (<https://cnsgenomics.com/software/gctb/#Genome-wideFine-mappinganalysis>). Online tool  
795 for predicting fine-mapping power: <https://sbayes.pctgplots.cloud.edu.au/shiny/power/>.

796

### 797 **Acknowledgements**

798 This research was supported by Australian National Health and Medical Research Council  
799 (1177268, 1113400), the Australian Research Council (FL180100072, DP220101947,  
800 DP230101352) and the National Institute of Mental Health (5R01MH121545-05). This study  
801 makes use of data from the UK Biobank (project ID: 12505).

802

### 803 **Author Contributions**

804 J.Z. conceived and supervised the study. J.Z. and Y.W. developed the methods. J.Z., P.M.V. and Y.W.  
805 designed the experiment. Y.W. conducted all analyses with the assistance or guidance from J.Z.,  
806 Z.Z., L.T., P.M.V., N.R.W. and M.E.G.. Y.W., and J.Z. wrote the manuscript with the participation of  
807 all authors. All the authors approved the final version of the manuscript.

808

### 809 **Competing Interests**

810 The authors declare no competing interests.

811

### 812 **References**

- 813 1 Visscher, P. M. *et al.* 10 Years of GWAS Discovery: Biology, Function, and Translation. *The*  
814 *American Journal of Human Genetics* **101**, 5-22, doi:10.1016/j.ajhg.2017.06.005 (2017).
- 815 2 Visscher, P. M., Brown, M. A., McCarthy, M. I. & Yang, J. Five years of GWAS discovery. *Am*  
816 *J Hum Genet* **90**, 7-24, doi:10.1016/j.ajhg.2011.11.029 (2012).
- 817 3 Abdellaoui, A., Yengo, L., Verweij, K. J. H. & Visscher, P. M. 15 years of GWAS discovery:  
818 Realizing the promise. *Am J Hum Genet* **110**, 179-194, doi:10.1016/j.ajhg.2022.12.011  
819 (2023).


- 820 4 Uffelmann, E. *et al.* Genome-wide association studies. *Nature Reviews Methods Primers* **1**,  
821 59, doi:10.1038/s43586-021-00056-9 (2021).
- 822 5 Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based  
823 Linkage Analyses. *The American Journal of Human Genetics* **81**, 559-575,  
824 doi:<https://doi.org/10.1086/519795> (2007).
- 825 6 Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics  
826 identifies additional variants influencing complex traits. *Nature Genetics* **44**, 369-375,  
827 doi:10.1038/ng.2213 (2012).
- 828 7 Wu, Y., Zheng, Z., Visscher, P. M. & Yang, J. Quantifying the mapping precision of genome-  
829 wide association studies using whole-genome sequencing data. *Genome Biology* **18**, 86,  
830 doi:10.1186/s13059-017-1216-0 (2017).
- 831 8 Farh, K. K.-H. *et al.* Genetic and epigenetic fine mapping of causal autoimmune disease  
832 variants. *Nature* **518**, 337-343, doi:10.1038/nature13835 (2015).
- 833 9 Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate causal  
834 variants by statistical fine-mapping. *Nature Reviews Genetics* **19**, 491-504,  
835 doi:10.1038/s41576-018-0016-z (2018).
- 836 10 Stephens, M. False discovery rates: a new deal. *Biostatistics* **18**, 275-294,  
837 doi:10.1093/biostatistics/kxw041 (2016).
- 838 11 Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A Simple New Approach to Variable  
839 Selection in Regression, with Application to Genetic Fine Mapping. *Journal of the Royal*  
840 *Statistical Society Series B: Statistical Methodology* **82**, 1273-1300,  
841 doi:10.1111/rssb.12388 (2020).
- 842 12 Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-  
843 wide association studies. *Bioinformatics* **32**, 1493-1501,  
844 doi:10.1093/bioinformatics/btw018 (2016).
- 845 13 Cui, R. *et al.* Improving fine-mapping by modeling infinitesimal effects. *Nature Genetics*,  
846 doi:10.1038/s41588-023-01597-3 (2023).
- 847 14 Zou, Y., Carbonetto, P., Wang, G. & Stephens, M. Fine-mapping from summary data with  
848 the “Sum of Single Effects” model. *PLOS Genetics* **18**, e1010299,  
849 doi:10.1371/journal.pgen.1010299 (2022).
- 850 15 Chen, W. *et al.* Fine Mapping Causal Variants with an Approximate Bayesian Method Using  
851 Marginal Test Statistics. *Genetics* **200**, 719-736, doi:10.1534/genetics.115.176107 (2015).
- 852 16 Yang, Z. *et al.* CARMA is a new Bayesian model for fine-mapping in genome-wide  
853 association meta-analyses. *Nature Genetics* **55**, 1057-1065, doi:10.1038/s41588-023-  
854 01392-0 (2023).

- 855 17 Kichaev, G. *et al.* Integrating Functional Data to Prioritize Causal Variants in Statistical  
856 Fine-Mapping Studies. *PLOS Genetics* **10**, e1004722, doi:10.1371/journal.pgen.1004722  
857 (2014).
- 858 18 Kichaev, G. & Pasaniuc, B. Leveraging Functional-Annotation Data in Trans-ethnic Fine-  
859 Mapping Studies. *The American Journal of Human Genetics* **97**, 260-271,  
860 doi:<https://doi.org/10.1016/j.ajhg.2015.06.007> (2015).
- 861 19 Weissbrod, O. *et al.* Functionally informed fine-mapping and polygenic localization of  
862 complex trait heritability. *Nature Genetics* **52**, 1355-1363, doi:10.1038/s41588-020-  
863 00735-5 (2020).
- 864 20 Zhang, Y., Qi, G., Park, J.-H. & Chatterjee, N. Estimation of complex effect-size distributions  
865 using summary-level statistics from genome-wide association studies across 32 complex  
866 traits. *Nature Genetics* **50**, 1318-1326, doi:10.1038/s41588-018-0193-x (2018).
- 867 21 Erbe, M. *et al.* Improving accuracy of genomic predictions within and between dairy cattle  
868 breeds with imputed high-density single nucleotide polymorphism panels. *J Dairy Sci* **95**,  
869 4114-4129, doi:10.3168/jds.2011-5019 (2012).
- 870 22 MacLeod, I. M. *et al.* Exploiting biological priors and sequence variants enhances QTL  
871 discovery and genomic prediction of complex traits. *BMC Genomics* **17**, 144,  
872 doi:10.1186/s12864-016-2443-6 (2016).
- 873 23 Habier, D., Fernando, R. L., Kizilkaya, K. & Garrick, D. J. Extension of the bayesian alphabet  
874 for genomic selection. *BMC Bioinformatics* **12**, 186, doi:10.1186/1471-2105-12-186  
875 (2011).
- 876 24 Lloyd-Jones, L. R. *et al.* Improved polygenic prediction by Bayesian multiple regression on  
877 summary statistics. *Nature Communications* **10**, 5086, doi:10.1038/s41467-019-12653-  
878 0 (2019).
- 879 25 Cleveland, M. A., Forni, S., Deeb, N. & Maltecca, C. Genomic breeding value prediction using  
880 three Bayesian methods and application to reduced density marker panels. *BMC*  
881 *Proceedings* **4**, S6, doi:10.1186/1753-6561-4-S1-S6 (2010).
- 882 26 Moser, G. *et al.* Simultaneous Discovery, Estimation and Prediction Analysis of Complex  
883 Traits Using a Bayesian Mixture Model. *PLOS Genetics* **11**, e1004969,  
884 doi:10.1371/journal.pgen.1004969 (2015).
- 885 27 Zheng, Z. *et al.* Leveraging functional genomic annotations and genome coverage to  
886 improve polygenic prediction of complex traits within and between ancestries. *Nature*  
887 *Genetics*, doi:10.1038/s41588-024-01704-y (2024).
- 888 28 Xiang, R. *et al.* Genome-wide fine-mapping identifies pleiotropic and functional variants  
889 that predict many traits across global cattle populations. *Nature Communications* **12**, 860,  
890 doi:10.1038/s41467-021-21001-0 (2021).


- 891 29 Shrestha, M. *et al.* Evaluation of Bayesian Linear Regression Models as a Fine Mapping  
892 tool. *bioRxiv*, 2023.2009.2001.555889, doi:10.1101/2023.09.01.555889 (2024).
- 893 30 Carbonetto, P. & Stephens, M. Scalable Variational Inference for Bayesian Variable  
894 Selection in Regression, and Its Accuracy in Genetic Association Studies. *Bayesian Analysis*  
895 **7**, 73-108, 136 (2012).
- 896 31 Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex  
897 traits. *Nature Genetics* **50**, 746-753, doi:10.1038/s41588-018-0101-4 (2018).
- 898 32 Zeng, J. *et al.* Widespread signatures of natural selection across human complex traits and  
899 functional genomic categories. *Nature Communications* **12**, 1164, doi:10.1038/s41467-  
900 021-21446-3 (2021).
- 901 33 Spain, S. L. & Barrett, J. C. Strategies for fine-mapping complex traits. *Human Molecular*  
902 *Genetics* **24**, R111-R119, doi:10.1093/hmg/ddv260 (2015).
- 903 34 Gong, Y., Greenbaum, J. & Deng, H. W. A statistical approach to fine-mapping for the  
904 identification of potential causal variants related to human intelligence. *J Hum Genet* **64**,  
905 781-787, doi:10.1038/s10038-019-0623-3 (2019).
- 906 35 Kamiza, A. B. *et al.* Multi-trait discovery and fine-mapping of lipid loci in 125,000  
907 individuals of African ancestry. *Nature Communications* **14**, 5403, doi:10.1038/s41467-  
908 023-41271-0 (2023).
- 909 36 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.  
910 *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 911 37 Finucane, H. K. *et al.* Partitioning heritability by functional annotation using genome-wide  
912 association summary statistics. *Nature Genetics* **47**, 1228-1235, doi:10.1038/ng.3404  
913 (2015).
- 914 38 Gazal, S. *et al.* Functional architecture of low-frequency variants highlights strength of  
915 negative selection across coding and non-coding annotations. *Nature Genetics* **50**, 1600-  
916 1607, doi:10.1038/s41588-018-0231-8 (2018).
- 917 39 Hou, K. *et al.* Causal effects on complex traits are similar for common variants across  
918 segments of different continental ancestries within admixed individuals. *Nature Genetics*  
919 **55**, 549-558, doi:10.1038/s41588-023-01338-6 (2023).
- 920 40 Yengo, L. *et al.* A saturated map of common genetic variants associated with human height.  
921 *Nature* **610**, 704-712, doi:10.1038/s41586-022-05275-y (2022).
- 922 41 Trubetsky, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in  
923 schizophrenia. *Nature* **604**, 502-508, doi:10.1038/s41586-022-04434-5 (2022).
- 924 42 de Lange, K. M. *et al.* Genome-wide association study implicates immune activation of  
925 multiple integrin genes in inflammatory bowel disease. *Nature Genetics* **49**, 256-261,  
926 doi:10.1038/ng.3760 (2017).

- 927 43 Lee, Sang H., Wray, Naomi R., Goddard, Michael E. & Visscher, Peter M. Estimating Missing  
928 Heritability for Disease from Genome-wide Association Studies. *The American Journal of*  
929 *Human Genetics* **88**, 294-305, doi:10.1016/j.ajhg.2011.02.002 (2011).
- 930 44 Yang, J., Wray, N. R. & Visscher, P. M. Comparing apples and oranges: equating the power  
931 of case-control and quantitative trait association studies. *Genet Epidemiol* **34**, 254-257,  
932 doi:10.1002/gepi.20456 (2010).
- 933 45 Novo, I., López-Cortegano, E. & Caballero, A. Highly pleiotropic variants of human traits  
934 are enriched in genomic regions with strong background selection. *Human Genetics* **140**,  
935 1343-1351, doi:10.1007/s00439-021-02308-w (2021).
- 936 46 Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.  
937 *New England Journal of Medicine* **373**, 895-907, doi:10.1056/NEJMoa1502214 (2015).
- 938 47 Li, A. *et al.* mBAT-combo: A more powerful test to detect gene-trait associations from  
939 GWAS data. *The American Journal of Human Genetics* **110**, 30-43,  
940 doi:<https://doi.org/10.1016/j.ajhg.2022.12.006> (2023).
- 941 48 Li, S. *et al.* The schizophrenia-associated missense variant rs13107325 regulates  
942 dendritic spine density. *Transl Psychiatry* **12**, 361, doi:10.1038/s41398-022-02137-z  
943 (2022).
- 944 49 Singh, T. *et al.* Rare coding variants in ten genes confer substantial risk for schizophrenia.  
945 *Nature* **604**, 509-516, doi:10.1038/s41586-022-04556-w (2022).
- 946 50 Dai, Z.-M. *et al.* SECISBP2L-Mediated Selenoprotein Synthesis Is Essential for Autonomous  
947 Regulation of Oligodendrocyte Differentiation. *The Journal of Neuroscience* **42**, 5860-5869,  
948 doi:10.1523/jneurosci.2141-21.2022 (2022).
- 949 51 Sazonovs, A. *et al.* Large-scale sequencing identifies multiple genes and rare variants  
950 associated with Crohn's disease susceptibility. *Nature Genetics* **54**, 1275-1283,  
951 doi:10.1038/s41588-022-01156-2 (2022).
- 952 52 Hutchinson, A., Watson, H. & Wallace, C. Improving the coverage of credible sets in  
953 Bayesian genetic fine-mapping. *PLOS Computational Biology* **16**, e1007829,  
954 doi:10.1371/journal.pcbi.1007829 (2020).
- 955 53 Samaddar, A., Maiti, T. & de los Campos, G. Bayesian Hierarchical Hypothesis Testing in  
956 Large-Scale Genome-Wide Association Analysis. *bioRxiv*, 2024.2002.2026.582204,  
957 doi:10.1101/2024.02.26.582204 (2024).
- 958 54 O'Connor, L. J. *et al.* Extreme Polygenicity of Complex Traits Is Explained by Negative  
959 Selection. *The American Journal of Human Genetics* **105**, 456-476,  
960 doi:10.1016/j.ajhg.2019.07.003 (2019).
- 961 55 Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex  
962 trait gene targets. *Nature Genetics* **48**, 481-487, doi:10.1038/ng.3538 (2016).

963  
964



965  
 966 **Figure 1** Schematic overview of genome-wide fine-mapping analysis using GBMM. GBMM  
 967 requires the GWAS summary statistics and genome-wide LD reference to fine-map the likely  
 968 causal variants for complex traits, and can incorporate functional annotations. Compared to  
 969 regional-based fine-mapping approaches, GBMM estimates priors with genome-wide SNPs and  
 970 MCMC sampling algorithm, and is more flexible on the assumption of the underlying distribution  
 971 of causal effects (**Table S1**). The illustration was created with BioRender.com.




972

973 **Figure 2** Comparison in the calibration of PIP between GBMM and existing fine-mapping methods  
974 under simulations with various genetic architectures. Shown are relationship between PIP and  
975 the true discovery rate across 100 PIP bins. Results showed in each column correspond to the  
976 results from GBMM (SBayesC and SBayesRC), SuSiE-inf and FINEMAP-inf and SuSiE and  
977 FINEMAMP respectively. Results shown in each row correspond to the sparse genetic  
978 architecture, major gene genetic architecture and LDMS architecture respectively.


979





980


981 **Figure 3** Comparison in local credible set (LCS) between SBayesRC and SuSiE-inf. Shown in  
982 panels (a-c) are power comparison between SBayesRC and SuSiE-inf at the same alpha cutoff.  
983 Shown in panels (d-f) are credible size comparison between SBayesRC and SuSiE-inf at the same  
984 alpha cutoff. Results showed in each column correspond to the simulation under sparse model (a,  
985 and d), major gene model (b and e) and LDMS model (c and f).



986


987 **Figure 4** Comparisons of mapping precision, independent sample replication, and effect size  
 988 estimation bias among fine-mapping methods. Panel (a-c) shows the distance between the causal  
 989 variants and the SNPs identified by different methods at PIP of 0.9 in simulations based on sparse  
 990 (a), large effects (b) and LDMS (c) genetic architectures (**Methods**). Panel (d-e) show the  
 991 replication rate of discovery using different methods at a given PIP threshold in the replication

992 sample (x-axis) using simulations (d) and real data analysis for height in the UKB (e). Simulations  
993 are based on a sparse model and results in (d) are the mean values over ten simulation replicates.  
994 Panel (f-g) show the regression of the estimated marginal effect size in replication samples on the  
995 estimated joint effect size in discovery samples using different fine-mapping methods. Dash line  
996 shows the regression slope, which is closer to one for a less biased method. The marginal effect  
997 estimated in the independent replication samples was used as a proxy to the true value because  
998 it is an unbiased estimate. The brown solid line is the  $y=x$  line.  
999




1000

1001 **Figure 5** Out-of-sample prediction accuracy using identified variants from different fine-mapping  
 1002 methods. (a) Comparison of the prediction R<sup>2</sup> using the fine-mapped SNPs from different methods  
 1003 in the simulation based on the sparse architecture (**Methods**). The number above each bar is the  
 1004 number of fine-mapped SNPs from each method at different PIP cut-offs. (b) Comparison of trans-  
 1005 ancestry prediction accuracy using fine-mapped variants from SBayesRC and SuSiE-inf from the  
 1006 analysis of samples of European ancestry for 6 complex traits in the UK Biobank, with variants  
 1007 with PIP > 0.9. (c) The relationship between trans-ancestry prediction transferability and PIP in  
 1008 European ancestry. The transferability was computed as non-EUR-R<sup>2</sup>/ EUR-R<sup>2</sup>. The solid lines are  
 1009 regression lines across traits in each ancestry. Results are the mean values over 100 simulation  
 1010 replicates.




1011  
 1012 **Figure 6** Projection of genome-wide fine-mapping outcomes to the theoretical power prediction  
 1013 in complex traits with diverse genetic architectures. (a-c) show the results of SBayesRC  
 1014 estimation for the SNP-based heritability ( $h_{SNP}^2$ ) (a), the proportions of  $h_{SNP}^2$  explained by  
 1015 different mixture components (b), and the proportions of SNPs with effects from different  
 1016 mixture components ( $\pi$ ) (c), for the simulated trait, height, Crohn's disease (CD), schizophrenia  
 1017 (SCZ), and high density lipoprotein (HDL). (d-e) shows the theoretical prediction of the power of  
 1018 identifying causal variants (d) and the proportion of  $h_{SNP}^2$  explained by the identified causal  
 1019 variants at different GWAS sample sizes for these traits. Dot shows the observed trait outcome  
 1020 based on local credible sets (including singleton LCSs) identified from SBayesRC. Note that the  
 1021 results shown in (a, c) were used as input data for our method that predicts fine-mapping power  
 1022 given sample sizes (d-e).



1023

1024 **Figure 7** Theoretical identification and prediction of genome-wide credible SNPs across 48  
1025 independent complex traits. Panel (a-b) shows the theoretical prediction of power and  
1026 proportion of SNP-based heritability explained by GCS SNPs at different GWAS sample sizes for  
1027 the 48 complex traits, respectively. Panel (c) shows the proportion of identified GCS SNPs at  
1028 different alpha threshold (proportion of causal variants captured) for the 48 complex traits  
1029 (average sample size = 291K). Panel (d) shows the proportion of  $h_{SNP}^2$  explained by the GCS SNPs  
1030 at different alpha threshold. Colours indicate different trait categories.

1031



1032

1033 **Figure 8** Genome-wide fine-mapping with functional annotations helped pinpoint the putative

1034 causal variants. Panel (a) shows enrichment of the genome-wide fine-mapped SNPs from

1035 SBayeRC and GWAS clumped SNPs in the 22 main functional categories defined in the LDSC

1036 baseline model. Panel (b) shows the prioritized causal variant at the *FTO* locus for BMI. The top

1037 track shows the *FTO* locus plot of the standard GWAS for BMI, and the second track shows the

1038 similar plot but with the PIP from SBayesRC for BMI. The starred SNP is the known causal variant  
1039 (rs1421085) for obesity at the *FTO* locus supported by previous functional studies. Panel (c)  
1040 shows the per-SNP heritability enrichment for the causal variant (rs1421085), the GWAS lead  
1041 variant (rs11642015) and the secondary signal (rs76488452) for BMI at the *FTO* locus. The  
1042 annotations on the x-axis were those present at least once in these three variants, excluding  
1043 quantitative annotations and duplicated annotations with flanking windows. Panel (d) shows the  
1044 prioritized causal variant at the *SLC39A8* locus for SCZ. The top track shows the *SLC39A8* locus  
1045 plot of the standard GWAS for SCZ, and the second track shows the similar plot but with the PIP  
1046 from SBayesRC for SCZ. The starred SNP is the missense variant (rs13107325) fine-mapped for  
1047 SCZ at the *SLC39A8* locus. Panel (e) shows the per-SNP heritability enrichment for the causal  
1048 variant (rs13107325) and the secondary signal (rs34333163) for SCZ at the *SLC39A8* locus.  
1049  
1050